Skip to nav Skip to content

Clinical Trial Search

296 Clinical Trials Found

Clinical Trial 20831

A Phase 1b/3 Double-Blind, Randomized,Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
PI: Gaballa, Sameh

Clinical Trial 22305

Disease Site: Breast, Lung, Other Respiratory and Intrathoracic Organs
PI: Soyano Muller, Aixa

Clinical Trial 22713

Disease Site: Any Site
PI: Soyano Muller, Aixa

Clinical Trial 21634

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
Disease Site: Non-Hodgkin's Lymphoma
PI: Bello, Celeste

Clinical Trial 20938

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors Between 1-4 cm
Disease Site: Lung
PI: Chiappori, Alberto

Clinical Trial 21140

Disease Site: Larynx, Lip, Oral Cavity and Pharynx
PI: Caudell, Jimmy

Clinical Trial 20955

A Phase II Study of Binimetinib plus Belinostat for Subjects with Metastatic Uveal Melanoma
Disease Site: Other Skin
PI: Tarhini, Ahmad

Clinical Trial 21415

Disease Site: Other Hematopoietic
PI: Kuykendall, Andrew

Clinical Trial 22080

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
PI: Chavez, Julio

Clinical Trial 21056

Disease Site: Lymphoid Leukemia
PI: Sandoval-Sus, Jose

Clinical Trial 20923

A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Disease Site: Leukemia, other, Myeloid and Monocytic Leukemia
PI: Elmariah, Hany

Clinical Trial 20494

A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Disease Site: Melanoma, skin
PI: Tarhini, Ahmad